摘要
目的 :比较非诺贝特微丸缓释胶囊与辛伐他汀治疗中国人群中混合型高脂血症的有效性和安全性。方法 :选择符合入选条件的混合型高脂血症病人 143例 ,随机分为非诺贝特组 72例 ,辛伐他汀组 71例 ,分别给予非诺贝特 2 5 0mg ,po ,qd及辛伐他汀 10mg ,po ,qd ,疗程均为 6wk。结果 :治疗6wk后 ,2组病人的TC ,TG ,LDL C及 (TC -HDL C) /HDL C均有非常显著的下降 ,HDL C有不同程度的升高。非诺贝特组TG水平降低较辛伐他汀组更显著 [(1.2± 0 .8)mmol·L- 1与 (0 .8± 0 .7)mmol·L- 1,P <0 .0 1],而辛伐他汀组降TC水平则明显高于非诺贝特组 ,分别为 (1.6± 1.0 )mmol·L- 1与(1.0± 1.0 )mmol·L- 1,P <0 .0 1;2组总体疗效接近 (92 %与 94 % ,P >0 .0 5 )。结论
AIM: To compare effect and safety of fenofibrate sustained release pellet capsule (Lip) vs simvastatin (Sim) in treating IIb hyperlipidemia in chinese crowds. METHODS: One hundred and forty-three patients with combined hyperlipidemia were randomly divided into two groups. Lip group (n=72) was treated with fenofibrate 250 mg·d -1, po, qd for 6 wk while Sim group (n=71) was treated with simvastatin 10 mg·d -1, po, qd for 6 wk. RESULTS: TC, TG, LDL-C, and (TC-HDL-C)/HDL-C in both groups significantly reduced after 6 wk treatment. The HDL-C increased in different degree. The reduction of serum TG was more significant in Lip group than that in Sim group[ (1.2± 0.8) mmol·L -1 vs (0.8± 0.7) mmol·L -1,P< 0.01], while TC and LDL-C levels were significient higher in Sim group than those in Lip group [(1.6± 1.0) mmol·L -1 vs (1.0± 1.0) mmol·L -1, P< 0.01] . There was no significant difference in total efficacy between two groups (92% vs 94%) (P> 0.05). CONCLUSION: Fenofibrate is an effective and safe drug in treating IIb hyperlipidemia as well as simvastatin.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第9期553-556,共4页
Chinese Journal of New Drugs and Clinical Remedies
